Reading an HPLC chromatogram on a peptide Certificate of Analysis

What HPLC purity actually measures

When a peptide Certificate of Analysis lists <strong>HPLC purity ≥ 99.4 %</strong>, that number is an <em>area-percent</em> calculation: the area under the main peak in the chromatogram, divided by the total area under all peaks above the detection threshold, expressed as a percentage. It is not a mass purity, an enantiomeric purity, or an absolute content assay. Understanding the distinction matters when you compare lots, suppliers, or analytical methods — because two labs running matched samples on different methods will report different numbers, and neither is wrong. [1]

Reversed-phase HPLC at 220 nm is the standard for peptide release testing because the amide bond absorbs strongly at that wavelength. Smaller peaks that elute alongside the main peak represent compounds that absorb at the same wavelength: synthesis-related impurities (truncated sequences, deletion peptides, oxidation forms), and degradation products that have accumulated since synthesis. Compounds that don't absorb at 220 nm — most inorganic salts, water, and a subset of residual solvents — are invisible to this measurement. That's why a release-quality COA includes other methods alongside HPLC. [2]

Anatomy of a clean peptide chromatogram

Pull up a sample chromatogram from a peptide reference standard — for instance the <a href="/product/cp-030">BPC-157 reference standard</a> or the <a href="/product/cp-001">Semaglutide reference standard</a>. A typical release chromatogram shows a single dominant peak at a consistent retention time, with a baseline that's flat before the peak and recovers to baseline after. The chromatogram is annotated with the column manufacturer, column length and pore size, mobile-phase gradient, flow rate, injection volume, and detector wavelength. All of those parameters need to match across runs for the integration numbers to mean the same thing. [3]

• <strong>Main peak</strong>: the target peptide. Its retention time is matched against a reference run on the same column-and-gradient combination. Drift in retention time between lots tells you something has changed in the analytical method, the sample, or both. [4]

• <strong>Shoulder peaks</strong>: usually deletion sequences (missing one residue) or oxidation forms of the target peptide. These are common when a methionine or tryptophan is in the sequence. [5]

• <strong>Late-eluting peaks</strong>: more hydrophobic impurities — often aggregated peptide, scavenger residues from solid-phase synthesis, or hydrophobic byproducts. [6]

• <strong>Early peaks near the dead volume</strong>: salts, water-soluble polar species, and the injection front. These are usually quantified separately and may not be included in the purity calculation depending on the integration method. [7]

How area-percent purity is calculated

The instrument's software integrates each peak's area and reports a table next to the chromatogram. The reported HPLC purity is the area of the main peak divided by the sum of all peaks that exceed the detection threshold, expressed as a percentage. Threshold settings matter — a lower threshold counts smaller impurity peaks and gives a lower reported purity for the same sample. Two labs using different thresholds on the same lot will report different numbers, even with identical instruments, columns, and gradients. [8]

Our released lots specify the threshold and the method in plain text on the COA. The threshold for most peptide reference standards is 0.05 % of the main-peak area — anything smaller is reported as "below threshold" and not counted in the purity calculation. This is the convention used by analytical laboratories servicing the pharmaceutical research industry. Two analytical conventions you'll see in the wild: <em>area-percent</em> (the area of the main peak divided by total area), and <em>HPLC purity by external standard</em> (the area of the main peak compared to a calibration curve of a known mass). They mean different things. Area-percent is what almost all peptide COAs report.

When two labs disagree on the same lot

Two labs running the same sample on different methods will report different purity numbers. A peptide that reads 99.4 % on a 30-minute gradient at 220 nm may read 98.7 % on a 60-minute gradient at 210 nm — the longer gradient resolves more peaks, and the shorter wavelength sees impurities the longer wavelength misses. The lab using more sample, a slower gradient, or a lower detection threshold will report lower purity. The lab making the opposite choices will report higher purity. Neither result is wrong; they're measuring different things.

When evaluating a peptide supplier, ask which method they use. A supplier whose COA specifies column manufacturer, gradient profile, wavelength, sample concentration, injection volume, and detection threshold is doing release-quality work. A supplier whose COA just says "99% pure by HPLC" without method detail is asking you to take their word for it. Our COAs list the method alongside the number for exactly this reason — see <a href="/research-guide/reading-a-coa">How to read a Certificate of Analysis</a> for the full COA literacy walkthrough.

What HPLC misses (and how a good COA covers the gap)

Reversed-phase HPLC at 220 nm has known blind spots. Inorganic salts don't absorb at 220 nm; counter-ions don't either. Water content can shift the effective mass per vial by 3–8 % without affecting the chromatogram. Residual solvents from synthesis (acetonitrile, TFA, DMF) often coelute with the injection front and don't show up as discrete peaks. Enantiomeric purity is invisible to a standard reversed-phase method. And HPLC says nothing about endotoxin content, which matters for any in-vitro work that touches cell culture.

This is why a release spec runs four orthogonal methods. Identity by HPLC-MS confirms the molecular ion within ±0.5 Da of the theoretical mass. Water content by Karl Fischer titration is reported separately. Residual solvents are screened by GC headspace against ICH Q3C limits. Endotoxin testing by LAL is available on request for lots earmarked for cell-culture-relevant work, with a release threshold of ≤ 5 EU/mg for those lots. The HPLC purity number is one piece of the picture, not the whole picture. A 99.4 % HPLC reading with 8 % water content has an effective mass purity closer to 91.4 % once you do the dilution arithmetic — and that matters for stoichiometric work like binding-affinity calibration.

Why content assay isn't the same as HPLC purity

A common source of confusion when reading a peptide COA: the difference between <em>HPLC area-percent purity</em> and a <em>content assay</em>. HPLC area-percent tells you what fraction of the UV-absorbing material at 220 nm is the target peptide. A content assay tells you how many milligrams of the target peptide are actually in the vial. The two numbers can disagree substantially — a vial filled to 5 mg nominal can contain anywhere from 4.2 to 5.0 mg of net peptide depending on the water content, counter-ion mass, and any residual non-absorbing salts that came along during lyophilisation.

For most in-vitro characterisation work — chromatographic comparator runs, retention-time benchmarking, identity confirmation — HPLC area-percent purity is the relevant figure. For stoichiometric work — receptor-binding K_d calibration, comparator quantification against in-house lots, ratio-controlled enzyme assays — content assay matters more than HPLC purity. Many release-quality COAs report both. Where only HPLC purity is reported, the water-content number (by Karl Fischer) is the rough proxy for missing mass: a lyophilized vial reading 99.5 % HPLC purity with 6 % water content is delivering roughly 93.5 % of nominal mass as target peptide, before counter-ions are accounted for.

Reading the impurity profile, not just the headline number

A 99.4 % HPLC purity reading masks a lot of structure. The same number could describe a lot with one large 0.5 % shoulder peak — a single deletion sequence or oxidation product, easy to characterise — or a lot with ten small 0.05 % impurity peaks scattered across the chromatogram, indicating less clean synthesis. For most in-vitro work the headline number is what matters. For method-development work or stability characterisation, the shape of the impurity profile tells you more than the area-percent integer.

Common impurity-profile signatures and what they suggest: <em>a single shoulder ~0.1–0.5 minutes earlier than the main peak</em> usually points to a deletion-sequence impurity (the synthesis missed a residue on a small fraction of the chains). <em>A shoulder ~0.1–0.3 minutes later than the main peak</em> often indicates an oxidation form — methionine sulfoxide or tryptophan oxidation product, especially relevant if those residues are in the sequence. <em>Late-eluting peaks beyond 1.5× the main retention time</em> usually represent more hydrophobic byproducts: scavenger residues, aggregated peptide, or capping-group adducts that survived the cleavage step. Reading these signatures on the lyophilized lot's release chromatogram tells you which degradation pathways to monitor in your downstream stability work.

Practical tips when reviewing an incoming COA

• Check the lot number on the COA matches the lot number printed on the vial label. Mismatches are the most common COA defect.

• Verify the analytical method (column, gradient, wavelength, threshold) is specified in plain text on the document — not just "HPLC purity ≥ 98 %" with no method.

• Look for a stated detection threshold. "Area-percent above 0.05 % of main peak" is the convention; if no threshold is stated, the supplier may be using a higher one to flatter the number.

• Cross-check the HPLC purity against the water content. A peptide reported at 99.5 % purity by HPLC but with 8 % water content has an effective mass purity closer to 91.5 % when you compute the dilution.

• If the lot is for stoichiometric work (binding-affinity calibration, comparator quantification), prefer lots with low water content (≤ 4 %) even if the HPLC purity is identical to a wetter lot.

• Verify the MS identity number — the chromatogram alone doesn't tell you the peak is your target peptide. A coeluting peak from a structurally similar impurity would inflate the HPLC purity without the MS confirming identity.

How we report HPLC on a Canada Peptides COA

Every reference standard we ship has a Certificate of Analysis attached that records: the main-peak retention time, the area-percent purity at the 0.05 % detection threshold, the column manufacturer and dimensions, the mobile-phase gradient timetable, the detector wavelength, the injection volume, and the sample concentration. The chromatogram itself is reproducible on a matched system — you can re-run the lot on your own analytical chain and the reported number is what you'll get within method tolerance.

Alongside HPLC we report identity by <a href="/research-guide/reading-a-coa">HPLC-MS</a> (mass within ±0.5 Da), water content by Karl Fischer titration (≤ 6.0 % w/w for most lots), residual solvents by GC headspace (within ICH Q3C limits), and and — on request for cell-culture-relevant lots — endotoxin by LAL with a threshold of ≤ 5 EU/mg. The four standard release lines (HPLC purity, HPLC-MS identity, Karl Fischer water, GC headspace residual solvents) appear on every COA; endotoxin testing is added when the lot is earmarked for cell-culture-relevant work. The independent analytical lab name appears on every COA — see the catalog for examples on <a href="/product/cp-001">Semaglutide</a>, <a href="/product/cp-002">Tirzepatide</a>, and <a href="/product/cp-003">Retatrutide</a>.

Summary

• HPLC purity is area-percent at 220 nm — not mass purity, not absolute content.

• It catches synthesis impurities; it doesn't catch salts, water, residual solvents, or non-absorbing material.

• Comparing purity numbers across labs is only meaningful when the method (column, gradient, wavelength, threshold) matches.

• On a release-quality peptide reference-standard COA, HPLC purity is reported alongside identity (HPLC-MS), water (Karl Fischer), residual solvents (GC headspace), and endotoxin (LAL) so the gaps in HPLC are filled by orthogonal methods.

• When the HPLC number alone doesn't tell you what you need (stoichiometric work, comparator calibration), cross-check against water content and identity mass before relying on the lot.

FAQ

Why is HPLC purity reported as a percent and not a quantity?

HPLC purity is a comparison between peak areas, not an absolute mass measurement. It tells you the relative composition of UV-absorbing material in the sample. For an absolute mass measurement of the peptide content per vial, see the 'Content assay' line on the COA when present, or run quantitative amino-acid analysis.

Can HPLC purity overstate purity if some impurities don't absorb at 220 nm?

Yes. Compounds that don't absorb strongly at the detection wavelength are under-counted or invisible. This is why a release-quality COA also reports water content (Karl Fischer), residual solvents (GC headspace), and identity (MS) — those methods catch what HPLC at 220 nm misses.

Why might two labs report different HPLC purity numbers for the same lot?

Different columns, gradients, sample concentrations, wavelengths, or integration thresholds produce different chromatograms. A peptide that reads 99.4% on a 30-minute gradient at 220 nm may read 98.7% on a 60-minute gradient at 210 nm. Always compare numbers from matched methods.

What detection threshold do you use on Canada Peptides COAs?

0.05% of the main-peak area. Anything smaller is reported as 'below threshold' and not counted in the purity calculation. This convention matches what release-grade analytical labs use for pharmaceutical reference materials.

Does HPLC tell me whether the peak is actually my target peptide?

On its own, no. A peak at the expected retention time is consistent with the target peptide but doesn't confirm it. Identity confirmation requires mass spectrometry — the MS portion of HPLC-MS measures the molecular ion and matches it against the theoretical mass of the target peptide within a stated tolerance (typically ±0.5 Da on a release-quality COA).

Frequently asked questions

References

1. Aguilar M. (n.d.). HPLC of Peptides and Proteins: Basic Theory and Methodology. HPLC of Peptides and Proteins. · DOI
2. Aguilar M. (n.d.). Reversed-Phase High-Performance Liquid Chromatography. HPLC of Peptides and Proteins. · DOI
3. Hearn M. (2002). Reversed-Phase and Hydrophobic Interaction Chromatography of Proteins and Peptides. Hplc Of Biological Macro- Molecules, Revised And Expanded. · DOI
4. Whitelegge J. (n.d.). HPLC and Mass Spectrometry of Intrinsic Membrane Proteins. HPLC of Peptides and Proteins. · DOI
5. Rauh M. (2012). LC–MS/MS for protein and peptide quantification in clinical chemistry. Journal of Chromatography B. · DOI
6. Roux S., Zékri E., Rousseau B. et al. (2007). Elimination and exchange of trifluoroacetate counter‐ion from cationic peptides: a critical evaluation of different approaches. Journal of Peptide Science. · DOI
7. Schoeffski K., Hoffmann H. (2010). Karl Fischer Titration: Determination of Water Content in Pharmaceuticals. Pharmaceutical Sciences Encyclopedia. · DOI
8. Connelly J. (2017). ICH Q3C Impurities. ICH Quality Guidelines. · DOI